Research Library
Clinical studies, systematic reviews, and meta-analyses — translated for general audiences and graded for evidence quality. Every summary links to the original source.
9+
Studies Summarized
4
Grade A Studies
9
Conditions Covered
Grade A — Strong Evidence
Consistent findings from multiple high-quality RCTs or systematic reviews. Sufficient to inform clinical recommendations.
Grade B — Moderate Evidence
Well-designed trials with some limitations, or consistent findings from observational studies. Promising but not definitive.
Grade C — Emerging Evidence
Preliminary findings from small trials or preclinical data. Insufficient for clinical recommendations but worth monitoring.
Featured Studies
High-impact research with the strongest evidence base.
Cannabidiol in Treatment-Resistant Epilepsy: A Systematic Review and Meta-Analysis
The Lancet Neurology, 2024
n=1,842 (14 RCTs)
Key Finding
39% median reduction in monthly convulsive seizures vs. placebo
Systematic review of 14 RCTs evaluating pharmaceutical-grade CBD (Epidiolex) in Dravet syndrome and Lennox-Gastaut syndrome. Demonstrated 39% median reduction in monthly convulsive seizure frequency versus placebo (95% CI: 31–47%). Favorable safety profile with somnolence and elevated liver enzymes as primary adverse events.
Cannabinoids for Chronic Neuropathic Pain: A Systematic Review of Randomized Controlled Trials
JAMA Internal Medicine, 2024
n=4,116 (32 RCTs)
Key Finding
Moderate evidence for pain reduction (SMD −0.52) across 32 RCTs
Comprehensive meta-analysis of 32 RCTs examining cannabinoid efficacy for neuropathic pain. Moderate evidence supporting cannabinoid use for pain reduction (SMD −0.52, 95% CI −0.68 to −0.36). THC-containing products showed greater efficacy than CBD alone. Adverse events were generally mild to moderate.
Cannabidiol for Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Trial
Neuropsychopharmacology, 2024
n=340
Key Finding
Significant GAD-7 reduction at 300mg/day; 58% response rate vs. 38% placebo
Double-blind RCT evaluating CBD 300mg/day vs. placebo over 12 weeks in adults with GAD. Significant reduction in GAD-7 scores at week 12 (−4.2 vs. −2.1, p<0.001). Response rate 58% vs. 38% placebo. Well-tolerated with no serious adverse events. Limitations: single dose tested, no active comparator.
Full Library
Filter by condition, cannabinoid, or evidence grade.
Showing 9 of 9 studies
Cannabidiol in Treatment-Resistant Epilepsy: A Systematic Review and Meta-Analysis
Key Finding
39% median reduction in monthly convulsive seizures vs. placebo
Cannabinoids for Chronic Neuropathic Pain: A Systematic Review of Randomized Controlled Trials
Key Finding
Moderate evidence for pain reduction (SMD −0.52) across 32 RCTs
Cannabidiol for Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Trial
Key Finding
Significant GAD-7 reduction at 300mg/day; 58% response rate vs. 38% placebo
Cannabis Use and Sleep Quality in Adults: A Prospective Cohort Study
Key Finding
Short-term sleep onset improvement; tolerance develops at 4–6 weeks
Nabiximols for Multiple Sclerosis Spasticity: Updated Meta-Analysis
Key Finding
44% of patients achieved ≥30% spasticity improvement vs. 23% placebo
Nabilone for PTSD-Associated Nightmares: A Randomized Crossover Trial
Key Finding
Significant nightmare reduction; improvements in overall PTSD symptom severity
CBD for Inflammatory Bowel Disease: Phase II Randomized Trial
Key Finding
Primary remission endpoint not met; significant CRP reduction and QoL improvement
Dronabinol for Cancer-Related Anorexia-Cachexia: Systematic Review
Key Finding
Consistent appetite improvement; FDA-approved for AIDS-related anorexia
Cannabigerol Attenuates Neuroinflammation in Murine Models of Parkinson's Disease
Key Finding
Significant neuroprotection in murine model; no human data yet
Our Methodology
Studies are selected based on publication in peer-reviewed journals, methodological quality, and clinical relevance. We prioritize RCTs, systematic reviews, and meta-analyses over observational and preclinical data.
Evidence grades follow a modified GRADE framework. Grade A requires consistent findings from multiple high-quality RCTs or systematic reviews. Grade B includes well-designed trials with limitations. Grade C covers preliminary or preclinical findings.
Important Limitations
- Research summaries are educational — not medical advice
- Cannabis research is rapidly evolving; grades may change as new evidence emerges
- Many studies use pharmaceutical-grade cannabinoids, not consumer products
- Individual responses to cannabinoids vary significantly
- Always consult a qualified clinician before making medical decisions